Effects of coenzyme Q10 (CoQ10) supplementation on semen quality and seminal oxidative stress of idiopathic oligoasthenoteratozoospermic (iOAT) infertile me

Completed

Conditions: Male infertility
Urological and Genital Diseases

Registration Number: ISRCTN29954277

Lead Sponsor: Iran University of Medical Sciences (Iran)

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Male

Target Recruitment: 60

Inclusion Criteria

1. Men 20-45 years
2. With idiopathic oligoasthenoteratozoospermia (sperm count 5-20 x 10^6/mL ,sperm motility according to World Health Organization (WHO) 1999 criteria <50% and normal sperm morphology <30%)
3. Seminal white blood cells <1 x 10^6/mL
4. At least 1 year of infertility
5. Normal serum levels of gonadotropines, testosterone and prolactine
6. Absence of systemic diseases, treatment with drug or supplement use in the 3 months before enrolment
7. Absence of infectious genital disease and anatomical abnormalities of the genital tract
8. Absence of smoking, drug addiction or alcohol consumption
9. Absence of occupational chemical exposure
10. Absence of surgical history on testis or vasodeferane

Exclusion Criteria

Discontinuation in supplement usage.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Super oxide dismutase and glutathione peroxidase activity of seminal plasma and 15-F2 alpha isoprostane concentration will be measured by commercial kits<br>2. Catalase activity of seminal plasma<br>3. Total antioxidant capacity of seminal plasma<br>4. Concentration of ubiquionone in seminal plasma will be measured by High Performance Liquid Chromatography (HPLC) at baseline and 3 months<br>5. Dietary intake will be assessed by 3 days dietary recall at baseline, 45 days and 3 months and will be analysed by nutrition analysis software (Food Processor II)<br><br>All primary outcomes will be assessed at baseline and 3 months

Secondary Outcome Measures

Name	Time	Method
1. Sperm morphology and motility will be assessed with spermiogeram in accordance with the WHO 1999 criteria and also by computer-assisted sperm analysis<br>2. Sperm DNA fragmentation will be measured by Sperm Chromatin Structure Analysis (SCSA)<br><br>All secondary outcomes will be assessed at baseline and 3 months